摘要
目的探讨安罗替尼胶囊联合GP方案对晚期非小细胞肺癌(NSCLC)的临床疗效及免疫调节作用。方法使用随机数字表法将2020年10月至2022年10月南京江北医院收治的40例晚期NSCLC患者分为两组。化疗组(20例)采用GP方案治疗,联合组(20例)在化疗组基础上给予安罗替尼胶囊治疗。检测两组患者治疗前及治疗后4个月的近期疗效、免疫功能指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、NK细胞)、FACT-L量表评分,记录两组患者不良反应发生率。结果治疗后联合组患者疾病控制率(95.00%vs 70.00%,χ^(2)=4.329,P=0.037)、治疗总有效率(70.00%vs 30.00%,χ^(2)=6.400,P=0.011)均优于化疗组;联合组患者治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、NK细胞均升高,且高于化疗组(P<0.05);治疗后两组FACT-L、KPS评分均升高,且联合组高于化疗组(P<0.05);联合组与化疗组不良反应总发生率差异无统计学意义(45.00%vs 30.00%,P>0.05)。结论对晚期NSCLC患者应用安罗替尼胶囊+GP方案治疗可提高整体治疗效果,有效改善患者免疫系统功能,且安全性高,有一定的临床应用价值。
Objective To explore the clinical efficacy and immunomodulatory effects of anlotinib capsule combined with GP regimen in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Forty patients with advanced NSCLC admitted to Nanjing Jiangbei Hospital from October 2020 to October 2022 were divided into two groups using a random number table method.The chemotherapy group(n=20)was treated with GP regimen,and the combined group(n=20)was treated with anlotinib capsule on the basis of the chemotherapy group.The short-term efficacy,immune function indexes(CD3^(+),CD4^(+),CD4^(+)/CD8^(+),NK cells)and FACT-L scale scores of the two groups were detected before treatment and 4 months after treatment,and the incidence of adverse reactions was recorded.Results After treatment,the disease control rate(95.00%vs 70.00%,χ^(2)=4.329,P=0.037)and the total effective rate(70.00%vs 30.00%,χ^(2)=6.400,P=0.011)of the combined group were better than those of the chemotherapy group.After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+),NK cells and FACT-L and KPS scores in the combined group were higher than those in the chemotherapy group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the combined group and the chemotherapy group(45.00%vs 30.00%,P>0.05).Conclusion Anlotinib capsule+GP regimen can improve the overall therapeutic effect of patients with advanced NSCLC,not only improve the function of the patient s immune system,but also has high safety,and has certain clinical application value.
作者
高金锋
胡萍
GAO Jinfeng;HU Ping(Department of Oncology,Nanjing Jiangbei Hospital Affiliated to Nantong University Xinglin College,Nanjing,Jiangsu 210048,China)
出处
《中国临床研究》
CAS
2024年第2期275-278,284,共5页
Chinese Journal of Clinical Research
关键词
非小细胞肺癌
晚期
安罗替尼胶囊
GP方案
免疫调节
化疗
Non-small cell lung cancer,advanced
Anlotinib capsules
GP protocol
Regulation of immunity
Chemotherapy
